Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Safety Study of Microlyte DualGuard (SAGGA)

6 de julio de 2026 actualizado por: Imbed Biosciences

Feasibility Clinical Trial to Assess the Safety and Potential Effectiveness of Microlyte® DualGuard Wound Dressing on Surgically Created Partial-thickness Donor Site Wounds on Patients Requiring Split- Thickness Skin Grafting; the SAGGA Trial

The primary purpose of this research is to evaluate the safety and effectiveness of Microlyte® DualGuard wound dressing in the healing of partial thickness donor site wounds, also known as skin graft donor sites. This research will assess wound healing, the occurrence of infection, allergic reaction, pain, and itching while subjects are in the hospital and after discharge. Subjects will complete clinic visits through 12 weeks. This research will also assess the occurrence of donor site wound infection, pain and itching, and scarring at 12 weeks, assessed by subjects using the Patient and Observer Scar Assessment Scale (POSAS).

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

This study is a multi-center randomized, controlled, open-label, split-wound clinical trial to assess the safety and potential effectiveness in wound healing of the Microlyte® DualGuard wound dressing in surgically created partial-thickness donor site wounds (DSW) on patients requiring split-thickness skin grafting.

This clinical trial is designed to demonstrate safety and effectiveness of the Microlyte® DualGuard wound dressing. We note that this clinical trial is designed for the management of surgically created clean acute donor-site wounds. These surgically clean acute wounds have high tendency to heal with the standard of care if supervised diligently, especially under the monitoring of a clinical trial.

Donor site wounds are created regularly in surgical hospitals as a means to utilize split-thickness skin grafts for closure of chronic, traumatic, infectious, oncologic, burn and other wounds. A donor site wound is a reproducible partial thickness wound. At the same time, it is associated with morbidity including pain, long healing times, risk of infection, and long-term cosmetic changes. Thus, it is the ideal model for assessment of safety and effectiveness of topical products engineered for wound healing and infection control. The donor site can easily be divided into two halves that are amenable to randomization using intra-patient controls to maximize the chances of assessing safety and effectiveness.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

53

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Brad Wiggins, BSN, RN, CBRN
  • Número de teléfono: 888-472-9898
  • Correo electrónico: bwiggins@imbedbio.com

Copia de seguridad de contactos de estudio

  • Nombre: Carrie M Huffman, MA, MPH, DLP, RAC-US
  • Número de teléfono: 301-337-8159
  • Correo electrónico: chuffman@imbedbio.com

Ubicaciones de estudio

  • Estados Unidos
    • Arizona
      • Phoenix, Arizona, Estados Unidos, 85008
        • Valleywise Health Medical Center
        • Contacto:
        • Investigador principal:
          • Kevin Foster, MD, MBA, FACS
    • District of Columbia
      • Washington D.C., District of Columbia, Estados Unidos, 20010
        • MedStar Washington Hospital Center
        • Contacto:
        • Investigador principal:
          • Jeffrey W Shupp, MD
    • Louisiana
      • New Orleans, Louisiana, Estados Unidos, 70112
        • University Medical Center New Orleans, LSU Health NOLA
        • Contacto:
          • Shana Lennard, RN, BSN, CCRP
          • Número de teléfono: 504-702-5171
          • Correo electrónico: slenna@lsuhsc.edu
        • Investigador principal:
          • Jeffrey E Carter, MD, FACS, FABA

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  1. Adult patients where creation of a donor site wound for any indication including chronic wound, burn wound, surgical/traumatic wound, and tumor excision is indicated.
  2. Thigh donor site wound (DSW) location.
  3. At least 22 years of age.
  4. Ability to understand and provide a signed and dated informed consent form.
  5. Stated willingness to comply with all study procedures and availability for all visits for the duration of the study.
  6. All female subjects of childbearing potential (not surgically sterile or postmenopausal) and male subjects with female partners of childbearing potential must agree to use effective contraception (such as implants, injectables, combined oral contraceptives, intrauterine device, sexual abstinence, vasectomy or vasectomized partner) for the duration of the study (84 days).
  7. Fitzpatrick Skin Type (FST I-VI) assessment and documentation at baseline. Subjects of all FST categories (I-VI) are eligible, and the enrollment strategy will ensure that the full range of FST is represented in the study population (10% minimum enrollment in each FST sub-category).

Exclusion Criteria:

  1. DSW size of > 310 cm2
  2. Calculated glomerular filtration rate (GFR) <60 ml/min
  3. Hypocalcemia defined as serum corrected calcium of <8.0 mg/dl
  4. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 1.5 times the upper limit of normal (ULN).
  5. Serum Creatinine > 2.0 mg/dL.
  6. Pregnant, lactating or nursing women.
  7. Unable to provide consent.
  8. Prior adverse reaction or known sensitivity to silver or gallium.
  9. Enrollment in another interventional trial using a systemic therapeutic within 30 days prior to enrollment for this study.
  10. Presumed impairment of wound healing as with prescription drugs or medical diagnoses that have potential to impair wound healing at the discretion of clinical investigator, e.g., cancer, transplant status, autoimmune disease, severe malnutrition, etc.
  11. Any diagnosis with concern for 30-Day mortality.
  12. Any condition that might impair the evaluation of subject safety or that in the investigator opinion would interfere with study requirements.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Treatment Arm - Proximal or Distal DSW location
Treatment with Microlyte DualGuard (investigational device)
Dispositivo: Microlyte DualGuard
Microlyte® DualGuard wound dressing: It is a sterile, single use synthetic polyvinyl alcohol absorbent sheet with ionic gallium, and with a polymeric surface coating containing ionic and metallic silver. It has very low amounts of silver and gallium with maximum of 0.16 mg/sq. in. and 1 mg/sq. in., respectively. Microlyte® DualGuard wound dressing absorbs wound fluid and forms a soft gel that conforms to the wound surface and maintains a moist environment. The dressing contains silver and gallium only to prevent or minimize microbial growth within the dressing.
Comparador activo: Standard of Care Arm - opposite side of DSW from treatment arm
The DSW will have a side (proximal or distal) that is randomized to Microlyte DualGuard. The opposite side (proximal or distal) will be treated with standard of care foam dressing (Allevyn).
Dispositivo: Allevyn Foam (Standard of Care Control)
Allevyn® is indicated for as wound management by secondary intention on shallow, granulating wounds, chronic and acute exuding wounds, full- and partial-thickness wounds including: leg ulcers, diabetic foot ulcers, surgical wounds, first- and second-degree burns, skin graft donor site, skin tears, and pressure injuries.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Periodo de tiempo
Incidence of wound closure defined as skin re-epithelialization without drainage or dressing requirements, confirmed at two consecutive study visits 2 weeks apart (Day 14 and Day 28)
Periodo de tiempo: From enrollment to Day 84
From enrollment to Day 84
Adverse event occurrence, including infection
Periodo de tiempo: From enrollment to Day 84
From enrollment to Day 84

Medidas de resultado secundarias

Medida de resultado
Periodo de tiempo
Debridement - yes or no
Periodo de tiempo: Enrollment to Day 84
Enrollment to Day 84
Pain as measured using a 10-point VAS
Periodo de tiempo: Enrollment to Day 84
Enrollment to Day 84
Itching as assessed using a 10-point VAS
Periodo de tiempo: Enrollment to Day 84
Enrollment to Day 84
Time, in days, to complete DSW closure
Periodo de tiempo: Enrollment to Day 84
Enrollment to Day 84
Percentage of donor site wound closure at Day 9
Periodo de tiempo: Enrollment to Day 9
Enrollment to Day 9
Quality of healing, evaluated using the Patient Observer Scare Assessment Scale (POSAS)
Periodo de tiempo: Day 84
Day 84
Durability of wound closure at 12 weeks
Periodo de tiempo: Day 84
Day 84

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Imbed Biosciences

Colaboradores

United States Department of Defense

Investigadores

  • Investigador principal: Kevin Foster, MD, MBA, FACS, Valleywise Health Medical Center

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

30 de agosto de 2026

Finalización primaria (Estimado)

1 de abril de 2027

Finalización del estudio (Estimado)

1 de agosto de 2027

Fechas de registro del estudio

Enviado por primera vez

6 de julio de 2026

Primero enviado que cumplió con los criterios de control de calidad

6 de julio de 2026

Publicado por primera vez (Actual)

10 de julio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

10 de julio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

6 de julio de 2026

Última verificación

1 de julio de 2026

Más información

Términos relacionados con este estudio

Palabras clave

Otros números de identificación del estudio

  • ID MIDRP 01
  • W81XWH-15-9-0001 (Otro identificador: Department of Defense)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir